Please login to the form below

Not currently logged in
Email:
Password:

Sanofi and Regeneron win CHMP nod for Dupixent

Atopic dermatitis treatment backed for European approval

Regeneron

European regulatory advisors have given their backing to Sanofi and Regeneron’s Dupixent (dupliumab).

The treatment for adults who are candidates for systemic therapy with moderate-to-severe atopic dermatitis received a positive opinion from this month’s meeting of the EMA’s Committee for Medicinal Products for Human Use (CHMP).

It makes it the first targeted biologic to receive a positive opinion from the CHMP for the disease to date, which could put it in a strong position once it receives marketing authorisation.

Dupixent is designed to specifically inhibit overactive signalling of two key proteins, IL-4 and IL-13, which are believed to be major drivers of the persistent underlying inflammation in atopic dermatitis.

The interleukin-4 (IL-4) and (IL-13) inhibitor will come in a pre-filled syringe for self-administration as a subcutaneous injection every other week and can be used with or without topical corticosteroids.

However, results from the CHRONOS trial showed that the product is even more effective at clearing skin lesions when used in combination with topical corticosteroids.

The CHMP based its opinion on studies from the global LIBERTY atopic dermatitis clinical trials, which incorporated data from nearly 3,000 adult patients with moderate-to-severe atopic dermatitis.

Those studies showed dupliumab avoids steroids and topical prescription therapies of immunosuppressant’s such as cyclosporine and methotrexate, which can cause side effects with chronic use.

In the US, Dupixent is already approved for the treatment of adults priced around $37,000 per patient per year, but had some bad press lately as Amgen sued Sanofi and Regeneron over the drug back in April claiming patient infringement.

In Europe the CHMP’s decisions almost always translate into full approval for the European Union and the final decision on this from the European Commission (EC) is expected in the next three months.

Article by
Gemma Jones

24th July 2017

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Grace Communications

Grace Communications is an award winning, independent, full service, creative communications agency specialising in solving problems for healthcare brands....

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics